Welcome to our dedicated page for Humana SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humana’s latest 10-K stretches well past 300 pages—packed with medical-loss ratios, Medicare Advantage Star Ratings, and CMS audit risk disclosures that can overwhelm even seasoned analysts. If you have ever tried to pinpoint how pharmacy benefit margins or risk-adjustment revenue affect earnings, you know the challenge.
Stock Titan removes that friction. Our AI reads every Humana annual report 10-K simplified, Humana quarterly earnings report 10-Q filing, and Humana 8-K material events explained the moment they post to EDGAR. You’ll see plain-English highlights of segment profitability, regulatory updates, and capital-return plans—plus instant alerts for Humana Form 4 insider transactions real-time.
- Track Humana insider trading Form 4 transactions to monitor executive sentiment.
- Compare medical-cost trends quarter over quarter with AI-tagged tables pulled directly from each filing.
- Review Humana proxy statement executive compensation to understand incentive alignment with Medicare growth.
Need deeper context? Use our “Explain� toggle for understanding Humana SEC documents with AI; it connects statutory language to real-world impact. Our coverage spans every form—from shelf registrations to the smallest 11-K—so you never miss a disclosure. Whether you’re running a DCF model, scanning an Humana earnings report filing analysis, or verifying Humana executive stock transactions Form 4, Stock Titan delivers the insights professionals rely on—without the regulatory maze.
Dyadic International, Inc. (Nasdaq: DYAI) filed a Form 8-K on 2 July 2025 to disclose a branding update. In 30 days the company will begin operating under the business name “Dyadic Applied BioSolutions.� The filing clarifies that the legal corporate name remains “Dyadic International, Inc.,� the DYAI ticker is unchanged, and the company will continue to trade on the Nasdaq Stock Market. The disclosure is provided under Item 7.01 (Regulation FD) and is furnished—not filed—thereby carrying no Section 18 liability and no direct impact on financial statements. No financial data, operational revisions, or strategic transactions are included; the report solely communicates the forthcoming DBA designation and furnishes the related press release as Exhibit 99.1.
Form 3 Overview: The filing discloses the initial beneficial ownership of Joshua T. Brumm, who became Chief Executive Officer and Director of Crescent Biopharma, Inc. following a two-step merger completed on 13 Jun 2025. At the Effective Time, GlycoMimetics, Inc. merged with Crescent Biopharma and simultaneously changed its corporate name to Crescent Biopharma, Inc., then converted from a Delaware corporation to a Cayman Islands exempted company on 16 Jun 2025.
Equity Holdings:
- 268,400 ordinary shares held directly via restricted stock units (RSUs) that vest 25 % on 17 Mar 2026 and 6.25 % quarterly thereafter through 17 Mar 2029.
- 805,200 stock options with a $6.16 exercise price, vesting 25 % on 17 Mar 2026 and monthly thereafter until 17 Mar 2029.
The filing confirms that all Pre-Merger Crescent equity awards automatically converted into equivalent Cayman ordinary-share instruments under identical terms. Brumm filed as a single reporting person and retains direct ownership of all disclosed securities.
Investor Relevance: The document affirms completion of the M&A transaction, finalizes the company’s redomiciling process, and reveals executive equity incentives that could add up to 1.07 million shares to the future float if fully vested and exercised.
FAQ
What is the current stock price of Humana (HUM)?
What is the market cap of Humana (HUM)?
What core services does Humana offer?
How does Humana generate revenue?
Who are the primary customers of Humana?
What differentiates Humana from other health insurers?
How is Humana positioned in the competitive health insurance market?
Does Humana offer services beyond traditional health insurance?
What industries and market segments does Humana serve?
How does Humana ensure quality in its healthcare delivery?
